Google
LIMN — LIMINATUS PHARMA, INC. CLASS A COMMON STOCK (Healthcare >> Biotechnology)
LIMN FAQ
What is LIMN's ROE?
LIMINATUS PHARMA, INC. CLASS A COMMON STOCK reports a Return on Equity (ROE) of 8,383.35%.
What is LIMN's dividend yield?
LIMINATUS PHARMA, INC. CLASS A COMMON STOCK offers a dividend yield of 0.00%.
What is LIMN's Deepscope Quality Score?
Deepscope rates LIMN's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LIMN?
Deepscope's AI Timing Score for LIMN is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LIMN belong to?
LIMINATUS PHARMA, INC. CLASS A COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.12
Price
-0.01
(-10.29%)
Day Change
|
|
|---|
LIMN, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROAが低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 92 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.12 |
| PBV / Sector |
-46.03 / 4.91
|
| Earning Per Share | -0.22 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
4.66 M
GREAT
|
| Average 1W Daily Value |
0.27 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-13 11:13:41 |
| Symbol | LIMN |
| Name | LIMINATUS PHARMA, INC. CLASS A COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 44.88 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 6.10 / 9,034.83 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 12611 Hiddencreek Way, Cerritos, CA, United States, 90703
Phone: 213 273 5453
Website: https://liminatuspharma.com
Sector: Healthcare >> Biotechnology
Description: Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
